The outcome of a positive Rituximab trial for ME/CFS – possibly, finally, an FDA approved drug, relief for many, acceptance for this disease, increased research funding – would have been spectacular but Dr. Mella reported this week in Norway that the trial failed.


The main objective of the Rituximab trial was not achieved but Rituximab’s role with ME/CFS is not necessarily over.

We won’t exactly how it failed until next year but the failure almost certainly means that Rituximab will not be the next FDA approved drug for ME/CFS.

That doesn’t mean Rituximab’s role in ME/CFS is necessarily over, however, and the Rituximab saga has brought much to the ME/CFS field. Read more about it in a Simmaron Research Foundation sponsored blog:

Norwegian Rituximab Chronic Fatigue Syndrome (ME/CFS) Trial Fails


Like the blog you're reading? Don't miss another one.

Get the most in-depth information available on the latest ME/CFS and FM treatment and research findings by registering for Health Rising's free  ME/CFS and Fibromyalgia blog here.

Stay on Top of the News!

Subscribe To Health Rising’s Free Information on Chronic Fatigue Syndrome (ME/CFS), Fibromyalgia (FM), Long COVID and Related Diseases.

Thank you for signing up!

Pin It on Pinterest

Share This